The Shares of Moderna Inc. inched 0.28% higher to $158.99 Tuesday. This proved to be an all-around dismal trading session for the Stock market, with the NASDAQ Composite Index COMP falling 0.09% to 13,389.43 and Dow Jones Industrial Average DJIA falling 1.36% to 34,269.16.
Moderna Inc. closed $30.27 below its 52-week high ($189.26), which the Company reached on February 8th. The stock outperformed some of its competitors Tuesday, as AbbVie Inc. ABBV fell 1.14% to $114.89, Amgen Inc. AMGN fell 0.13% to $252.30, and AstraZeneca PLC ADR AZN fell 0.51% to $54.10. Trading volume (8.1 M) remained 1.9 million below its 50-day average volume of 10.0 M.
New data of Moderna Inc shows a single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two variants of concern in vaccinated clinical trial participants. Initial analysis of Phase 2/3 TeenCOVE study of mRNA-1273 in adolescents ages 12 to 17 years showed vaccine efficacy against COVID-19 of 96%; mRNA-1273 was generally well tolerated with no serious safety concerns identified to date. Phase 3 study of mRNA-1273 in adults with a kidney or liver transplant is ongoing. The company plans to launch rolling submission for BLA in the U.S. this month